Summary of the included studies
| Study ID | Design | Population | Valve of TAVR (self vs balloon expandable) | Follow-up | Main findings |
| Watanabe et al16 | Japanese, multicentre registry (OCEAN-TAVI) | From October 2013 to August 2015, 749 patients with severe AS (47 with active cancer) underwent TAVR in 8 centres. | Balloon expandable | 1 year | Similar postprocedural outcomes at the 30-day follow-up. No significant differences in the all-cause mortality at the 30-day and 1-year follow-ups. |
| Mangner et al17 | Single-centre, prospective cohort study | From February 2006 to September 2014, 1821 patients with severe AS (99 with active cancer) underwent TAVR after a multidisciplinary heart team discussion. | Any | 1 year | Similar postprocedural and all-cause mortality outcomes at the 30-day follow-up, but the all-cause mortality was significantly higher in patients with active cancer at the 1-year follow-up. |
| Landes et al18 | Worldwide registry (TOP-AS) | From 2016 to January 2019, 2744 patients (222 with active cancer) underwent TAVR in 18 centres. | Any | Still ongoing | Similar postprocedural and all-cause mortality outcomes at the 30-day follow-up, but the all-cause mortality was significantly higher in patients with active cancer at the 1-year follow-up. |
AS, aortic stenosis; OCEAN-TAVI, Optimized Transcatheter Valvular Intervention; TAVR, transcatheter aortic valve replacement; TOP-AS, TAVR in Oncology Patients with Severe Aortic Stenosis.